Almost Half of Crohn's Disease Patients Achieved Endoscopic Response After One Year of Maintenance Treatment with AbbVie's Risankizumab

  • AbbVie Inc ABBV has announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing Skyrizi (risankizumab) achieved the co-primary endpoints of endoscopic response and clinical remission at one year in Crohn's disease.
  • After one year, 47% of patients receiving risankizumab achieved endoscopic response compared with 22% of patients in the induction-only control group.
  • A higher number of patients receiving risankizumab achieved clinical remission, with 52% on risankizumab versus 41% in the induction-only control group.
  • 39% of patients in the risankizumab group achieved endoscopic remission compared to 13% of the induction-only control group.
  • Deep remission was achieved by 29% of risankizumab treated patients versus 10% in the control group.
  • Price Action: ABBV shares are down 0.50% at $111.64 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsCrohn's DiseasePhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!